TABLE 5
FROM:
Fertility, gonadal and sexual function in survivors of testicular cancer
R A Huddart, A Norman, C Moynihan, A Horwich, C Parker, E Nicholls and D P Dearnaley
BACK TO ARTICLETable 5. Hormonal levels in patients with paired baseline and follow-up hormone profiles
| Chemotherapy | Chemotherapy/radiotherapy | Radiotherapy | Surveillance | Overall | |
|---|---|---|---|---|---|
| N | 146 | 46 | 61 | 114 | 367 |
| FSH (iu 1-1) | |||||
| Baseline | 4* (2–8) | 8 (3.75–19) | 7 (5–10) | 7 (4–10) | 6 |
| Follow-up | 10* (8–18) | 19* (9.25–31.75) | 10 (7–15.25) | 9 (6–13.25) | 10 |
| Difference | 6* (3–9.25) | 11* (4–19) | 3 (1–7) | 3 (1–5) | 4 |
| LH (iu 1-1) | |||||
| Baseline | 11* (6–38.75) | 9* (6–17.25) | 8 (5–10) | 6 (4–10) | 8 |
| Follow-up | 6* (4–9) | 8* (5–12) | 6* (4–8) | 5 (4–7) | 6 |
| Difference | –4* (-28.5 to -1) | -1 (-5.5–4.5) | -1 (-3–1.0) | -1 (-4–1.0) | -2 |
| Testosterone (nmol l-1) | |||||
| Baseline | 17* (13–21) | 13 (10–16) | 13 (11–16) | 13 (11–17) | 15 |
| Follow-up | 14 (11–17.5) | 12 (9–17) | 14 (10–16) | 14 (11–17) | 14 |
| Difference | -2* (-8–1.5) | -2 (-5.25–4.0) | -1 (-4–2.0) | 1 (-4–4.0) | -1 |
All baseline levels are postorchidectomy and prechemotherapy or radiotherapy. Follow-up samples are a minimum of 5 years post-treatment. The presented data are not normally distributed, so presented values in the table are median (interquartile range). Normal ranges as presented in Table 4.
*Statistically different to surveillance (P<0.01).
